# An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07371663/  
OnCo record `nct07371663` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TCC1727 tablet 90mg in non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer, endometrial cancer and melanoma, run by Beijing Tide Pharmaceutical Co., Ltd, now recruiting.

## Summary

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07371663 by Beijing Tide Pharmaceutical Co., Ltd, with 266 participants planned, started 2025-12-03 and due to reach its primary completion in 2028-09-30. Interventions recorded: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg and benmelstobart Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07371663
- Phase: 1/2
- Setting: An Open-Label, Multicenter Phase Ib/II Clinical Trial of TCC1727 in Combination With Benmelstobart/Olaparib/Topotecan for Advanced Solid Tumors
- Sponsor: Beijing Tide Pharmaceutical Co., Ltd
- Enrolled: 266

## Sources

- ClinicalTrials.gov NCT07371663: https://clinicaltrials.gov/study/NCT07371663

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Beijing Tide Pharmaceutical](https://onco.cc/companies/beijing-tide-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07371663.json